MIRM · XBRL financial data

Mirum Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MIRM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	70*	69	78	90	99*	112	128	133	149*	160	176	186
Selling, general and administrative	46*	46	49	51	57*	58	63	62	74*	96	81	89
Total operating expenses	102*	96	102	103	124*	127	133	130	153*	949	219	245
Operating income (loss)	(33)*	(26)	(24)	(13)	(24)*	(15)	(5)	3	(5)*	(789)	(43)	(60)
Interest income	4*	4	3	3	3*	3	3	3	3*	3	4	5
Interest expense	4*	4	4	4	4*	4	4	4	4*	4	3	2
Other income (expense)	(3)*	2	0	(1)	0*	2	0	0	(0)*	0	(24)	16
Income tax expense (benefit)	0*	1	1	0	(1)*	1	0	(0)	1*	0	2	1
Net income (loss)	(36)*	(25)	(25)	(14)	(24)*	(15)	(6)	3	(6)*	(790)	(67)	(41)
Earnings per share, basic USD per share	(0.77)*	(0.54)	(0.52)	(0.30)	(0.49)*	(0.30)	(0.12)	0.06	(0.11)*	(13.43)	(1.06)	(0.62)
Earnings per share, diluted USD per share	(0.77)*	(0.54)	(0.52)	(0.30)	(0.49)*	(0.30)	(0.12)	0.05	(0.13)*	(13.43)	(1.06)	(0.87)
Weighted average shares, basic millions of shares	47*	47	47	48	48*	49	50	51	52*	59	63	66
Weighted average shares, diluted millions of shares	47*	47	47	48	48*	49	50	57	45*	59	63	66

Fiscal quarters (MIRM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	286	303	233	223	223	212	228	282	297	325	331	243
Short-term investments	0	—	45	61	58	66	76	94	87	61	108	130
Marketable securities	—	—	45	61	58	66	76	94	87	61	108	130
Marketable securities, non-current	—	—	17	9	13	21	17	2	8	34	123	127
Accounts receivable	68	55	60	69	78	96	107	107	123	133	145	156
Inventory	22	22	20	22	22	22	23	24	25	26	26	25
Prepaid and other current assets	11	10	9	12	12	15	19	24	18	25	27	31
Total current assets	388	389	368	387	393	411	453	531	550	569	636	587
Property and equipment, net	1	1	1	1	1	1	1	1	2	2	2	3
Right-of-use asset	1	1	9	9	9	8	9	9	9	13	12	11
Total assets	647	652	661	668	671	690	726	785	843	891	1,045	1,027
Accounts payable	7	16	10	10	15	12	18	12	10	59	23	14
Accrued liabilities	79	90	101	105	110	—	—	—	196	—	—	—
Total current liabilities	87	106	112	116	127	128	145	160	206	273	223	283
Lease liability, non-current	1	0	8	8	8	7	8	7	8	11	10	10
Total liabilities	398	417	432	436	445	457	471	493	528	648	1,055	1,081
Accumulated deficit	(556)	(582)	(606)	(620)	(644)	(659)	(665)	(662)	(668)	(1,458)	(1,525)	(1,566)
Total stockholders' equity	249	235	229	232	226	233	255	292	315	242	(10)	(54)
Total liabilities and equity	647	652	661	668	671	690	726	785	843	891	1,045	1,027
Common shares outstanding (cover page) millions of shares	47	47	48	48	49	50	50	51	60	61	65	65

Fiscal quarters (MIRM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(36)*	(25)	(25)	(14)	(24)*	(15)	(6)	3	(6)*	(790)	(67)	(41)
Stock-based compensation	10*	11	12*	12*	13*	16	18*	18*	19*	36	31*	33*
Depreciation and amortization	5*	6	6*	6*	6*	6	6*	6*	6*	7	7*	7*
Net cash from operating activities	(17)*	15	(4)*	4*	(5)*	(2)	12*	40*	6*	(229)	(44)*	(4)*
Purchases of property and equipment	0*	0	1*	0*	0*	0	0*	0*	1*	1	0*	1*
Net cash from investing activities	(2)*	(0)	(73)*	(18)*	1*	(16)	(7)*	(2)*	1*	(12)	(160)*	(29)*
Proceeds from issuing common stock	0*	0	0*	0*	0*	—	—	—	year only	—	—	—
Net cash from financing activities	2*	1	7*	4*	5*	6	9*	16*	9*	270	211*	(54)*
Net change in cash	(17)*	17	(69)*	(10)*	(0)*	(11)	16*	54*	16*	28	6*	(88)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Mirum Pharmaceuticals	243	186	(4.3)*	65.3M	4.0 quarters	Q3 FY26 10-QSep 30, 2026
Acadia Pharmaceuticals	322	342	12*	172.8M	—	Q3 FY26 10-QSep 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	151	not reported	(160)*	799.8M	4.5 quarters	Q3 FY26 10-QSep 30, 2026
Cytokinetics	203	48	(124)*	139.3M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Vericel	133	85	18*	51.0M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 5, 2026, 10:48 PM ET. The filing on SEC.gov is the record.